Lexaria Bioscience (NASDAQ:LEXX) Posts Earnings Results

Lexaria Bioscience (NASDAQ:LEXX) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Zacks reports. Lexaria Bioscience had a negative return on equity of 86.10% and a negative net margin of 1,249.14%.

Lexaria Bioscience Trading Up 0.5 %

Shares of NASDAQ LEXX traded up $0.01 during midday trading on Friday, reaching $2.22. The company’s stock had a trading volume of 49,788 shares, compared to its average volume of 93,298. The company has a 50 day moving average price of $2.24 and a 200 day moving average price of $2.78. Lexaria Bioscience has a one year low of $1.36 and a one year high of $6.85. The company has a market cap of $38.75 million, a price-to-earnings ratio of -4.72 and a beta of 0.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Lexaria Bioscience in a report on Monday, December 2nd.

Insider Buying and Selling

In other news, CEO Richard Christopher purchased 22,828 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were acquired at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the completion of the acquisition, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at $51,134.72. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 26.40% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.